SCHEMBL6563180

SCHEMBL6563180

CCCC/C=C\CCCCCCCCCCN(N)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SOAT2 O75908 1/20 0.41
SOAT1 P35610 1/20 0.41
NPC1 O15118 1/20 0.40
JAK2 O60674 1/20 0.40
RAB9A P51151 1/20 0.40
PAX8 Q06710 1/20 0.40
EPHX2 P34913 5/20 0.40
FAAH O00519 2/20 0.40
KCNH2 Q12809 3/20 0.39
BID P55957 3/20 0.39
BCL2L1 Q07817 3/20 0.39
MCL1 Q07820 3/20 0.39
BAK1 Q16611 3/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6563182 1.00 SOAT2 (0.41) SOAT2SOAT1NPC1JAK2RAB9A
SCHEMBL6486950 0.92 SOAT2 (0.42) SOAT2SOAT1NPC1JAK2RAB9A
SCHEMBL6486956 0.92 SOAT2 (0.42) SOAT2SOAT1NPC1JAK2RAB9A
SCHEMBL6477122 0.90 EPHX2 (0.41) SOAT2SOAT1NPC1JAK2RAB9A
SCHEMBL6477117 0.90 EPHX2 (0.41) SOAT2SOAT1NPC1JAK2RAB9A
SCHEMBL6477185 0.86 NPC1 (0.50) NPC1JAK2RAB9APAX8KCNH2
SCHEMBL6488829 0.86 NPC1 (0.50) NPC1JAK2RAB9APAX8KCNH2
SCHEMBL6484775 0.86 NPC1 (0.50) NPC1JAK2RAB9APAX8KCNH2
SCHEMBL6487469 0.86 NPC1 (0.50) NPC1JAK2RAB9APAX8KCNH2
SCHEMBL6477702 0.86 NPC1 (0.50) NPC1JAK2RAB9APAX8KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP SOAT2 603/4885SOAT1 1375/4885NPC1 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.